{
    "id": 162,
    "name": "cancer",
    "source": "DOID",
    "definition": "A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis. [url:http\\://en.wikipedia.org/wiki/cancer, url:http\\://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=cancer]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:162",
    "evidence": [
        {
            "id": 808,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, cell lines transformed by MET M1268T were sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).",
            "molecularProfile": {
                "id": 965,
                "profileName": "MET M1268T"
            },
            "therapy": {
                "id": 1088,
                "therapyName": "K252a",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 451,
                    "pubMedId": 12118367,
                    "title": "K252a inhibits the oncogenic properties of Met, the HGF receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12118367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 809,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET M1268T demonstrated sensitivity to SU11274 treatment (PMID: 15064724).",
            "molecularProfile": {
                "id": 965,
                "profileName": "MET M1268T"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 452,
                    "pubMedId": 15064724,
                    "title": "The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15064724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 810,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET H1112Y demonstrated sensitivity to SU11274 treatment (PMID: 15064724).",
            "molecularProfile": {
                "id": 1120,
                "profileName": "MET H1112Y"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 452,
                    "pubMedId": 15064724,
                    "title": "The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15064724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET L1213V showed resistance to SU11274 treatment (PMID: 15064724).",
            "molecularProfile": {
                "id": 1121,
                "profileName": "MET L1213V"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 452,
                    "pubMedId": 15064724,
                    "title": "The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15064724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET Y1248H showed resistance to SU11274 treatment (PMID: 15064724).",
            "molecularProfile": {
                "id": 1122,
                "profileName": "MET Y1248H"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 452,
                    "pubMedId": 15064724,
                    "title": "The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15064724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET V1110I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",
            "molecularProfile": {
                "id": 1123,
                "profileName": "MET V1110I"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 455,
                    "pubMedId": 19783361,
                    "title": "Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19783361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 814,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET V1238I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",
            "molecularProfile": {
                "id": 1124,
                "profileName": "MET V1238I"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 455,
                    "pubMedId": 19783361,
                    "title": "Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19783361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 815,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET V1206I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",
            "molecularProfile": {
                "id": 1125,
                "profileName": "MET V1206L"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 455,
                    "pubMedId": 19783361,
                    "title": "Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19783361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 816,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line expressing MET H1112L demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",
            "molecularProfile": {
                "id": 1126,
                "profileName": "MET H1112L"
            },
            "therapy": {
                "id": 1089,
                "therapyName": "SU11274",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 455,
                    "pubMedId": 19783361,
                    "title": "Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19783361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 835,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).",
            "molecularProfile": {
                "id": 372,
                "profileName": "AKT1 wild-type"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 184,
                    "pubMedId": 23795919,
                    "title": "Characterization of a chemical affinity probe targeting Akt kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23795919"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 905,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273).",
            "molecularProfile": {
                "id": 1232,
                "profileName": "RET mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 589,
                    "pubMedId": 17664273,
                    "title": "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mdm2 T16A conferred moderate resistance to Nutlin-3a in vitro, possibly by affecting the dynamics of the Mdm2 lid region (aa 16-24) (PMID: 23653682).",
            "molecularProfile": {
                "id": 1876,
                "profileName": "MDM2 T16A"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 848,
                    "pubMedId": 23653682,
                    "title": "In vitro selection of mutant HDM2 resistant to Nutlin inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23653682"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1105,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mdm2 P20L conferred moderate resistance to Nutlin-3a in vitro, possibly by affecting the dynamics of the Mdm2 lid region (aa 16-24) (PMID: 23653682).",
            "molecularProfile": {
                "id": 1877,
                "profileName": "MDM2 P20L"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 848,
                    "pubMedId": 23653682,
                    "title": "In vitro selection of mutant HDM2 resistant to Nutlin inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23653682"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincial study, Mdm2 Q24R conferred resistance to Nutlin-3a in vitro, possibly by affecting the dynamics of the Mdm2 lid region (aa 16-24) and increasing Mdm2 affinity for Tp53 (PMID: 23653682).",
            "molecularProfile": {
                "id": 1878,
                "profileName": "MDM2 C305F"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 848,
                    "pubMedId": 23653682,
                    "title": "In vitro selection of mutant HDM2 resistant to Nutlin inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23653682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1107,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mdm2 M62V has been shown to confer resistance to Nutlin-3a in vitro, possibly by reducing Mdm2 affinity for nutlin (PMID: 23653682).",
            "molecularProfile": {
                "id": 1879,
                "profileName": "MDM2 M62V"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 848,
                    "pubMedId": 23653682,
                    "title": "In vitro selection of mutant HDM2 resistant to Nutlin inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23653682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mdm2 M62A conferred resistance to Nutlin-3a in vitro, possibly by reducing Mdm2 affinity for nutlin (PMID: 23653682).",
            "molecularProfile": {
                "id": 1880,
                "profileName": "MDM2 M62A"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 848,
                    "pubMedId": 23653682,
                    "title": "In vitro selection of mutant HDM2 resistant to Nutlin inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23653682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mdm2 L82P conferred resistance to Nutlin-3a in vitro, possibly by reducing Mdm2 affinity for nutlin (PMID: 23653682).",
            "molecularProfile": {
                "id": 1881,
                "profileName": "MDM2 L82P"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 848,
                    "pubMedId": 23653682,
                    "title": "In vitro selection of mutant HDM2 resistant to Nutlin inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23653682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mdm2 Q24R conferred resistance to Nutlin-3a in vitro, possibly by increasing Mdm2 affinity for Tp53 and by affecting the dynamics of the Mdm2 lid region (aa 16-24) (PMID: 23653682).",
            "molecularProfile": {
                "id": 1887,
                "profileName": "MDM2 Q24R"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 848,
                    "pubMedId": 23653682,
                    "title": "In vitro selection of mutant HDM2 resistant to Nutlin inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23653682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1154,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK1 F958V displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 912,
                "profileName": "JAK1 F958V"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1156,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK1 F958C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2045,
                "profileName": "JAK1 F958C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1157,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK1 F958L displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2046,
                "profileName": "JAK1 F958L"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1158,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK1 F958S displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2047,
                "profileName": "JAK1 F958S"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1159,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK1 P960T displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2053,
                "profileName": "JAK1 P960T"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1160,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK1 P960S displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2052,
                "profileName": "JAK1 P960S"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1161,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2064,
                "profileName": "JAK2 Y931C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1162,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1163,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring the JAK1 V658F/F958C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2066,
                "profileName": "JAK1 V658F JAK1 F958C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 A723D were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2040,
                "profileName": "JAK1 A723D"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1192,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 D895H were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2041,
                "profileName": "JAK1 D895H"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1193,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 E897K were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2042,
                "profileName": "JAK1 E897K"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1195,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 F734L were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2044,
                "profileName": "JAK1 F734L"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1196,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 K1026E were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2048,
                "profileName": "JAK1 K1026E"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1197,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 L783F were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2049,
                "profileName": "JAK1 L783F"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1198,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 L910Q were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2050,
                "profileName": "JAK1 L910Q"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1199,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 P815S were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2051,
                "profileName": "JAK1 P815S"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 R724S were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2054,
                "profileName": "JAK1 R724S"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 S1043I were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2055,
                "profileName": "JAK1 S1043I"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1202,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 S646F were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2056,
                "profileName": "JAK1 S646F"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1203,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 S703I were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2057,
                "profileName": "JAK1 S703I"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1204,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 T901R were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2058,
                "profileName": "JAK1 T901R"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1205,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing JAK1 V658F were sensitive to ATP-competitive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2059,
                "profileName": "JAK1 V658F"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1206,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 V658I were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2060,
                "profileName": "JAK1 V658I"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1207,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 Y1035C were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2062,
                "profileName": "JAK1 Y1035C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1208,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 Y652H were sensitive to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2063,
                "profileName": "JAK1 Y652H"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1209,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells harboring JAK1 V658L were sensitive to ATP-competetive JAK (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2061,
                "profileName": "JAK1 V658L"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1222,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).",
            "molecularProfile": {
                "id": 506,
                "profileName": "AKT2 wild-type"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 184,
                    "pubMedId": 23795919,
                    "title": "Characterization of a chemical affinity probe targeting Akt kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23795919"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1223,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).",
            "molecularProfile": {
                "id": 507,
                "profileName": "AKT3 wild-type"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 184,
                    "pubMedId": 23795919,
                    "title": "Characterization of a chemical affinity probe targeting Akt kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23795919"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1227,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the pan AKT inhibitor GSK2141795 displayed similar levels of inhibition against ATK1 E17K (activating mutation) as ATK1 wild-type (PMID: 24978597).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483).",
            "molecularProfile": {
                "id": 575,
                "profileName": "HRAS wild-type"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1008,
                    "pubMedId": 8620483,
                    "title": "The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8620483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1384,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, high dose tamoxifen demonstrated inhibition against Carm1, a type I arginine methyltransferase, suggesting this may be the mechanism of its therapeutic activity in estrogen receptor negative cancers (PMID: 21243720).",
            "molecularProfile": {
                "id": 2434,
                "profileName": "CARM1 wild-type"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1115,
                    "pubMedId": 21243720,
                    "title": "Xenoestrogens regulate the activity of arginine methyltransferases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21243720"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1478,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "Ubiquitination is a key mechanism regulating processes including inflammation, proliferation, cell survival, and apoptosis. Inactivation of deubiquitinating enzymes like CYLD has been identified in multiple cancers and tumor cells with Cyld inactivation show heightened invasion and proliferation suggesting a potential value for Cyld as a therapeutic target (PMID: 25375928).",
            "molecularProfile": {
                "id": 2596,
                "profileName": "CYLD inact mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1376,
                    "pubMedId": 25375928,
                    "title": "Ubiquitination in disease pathogenesis and treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25375928"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1480,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "Micro-RNAs (miRNAs) function as regulators of gene expression and mutations or aberrant expression is correlated with a variety of human cancers (PMID: 18685719). Preclinical studies demonstrate that upregulation of AGO1, a modulator of miRNA function, results in activation of multiple signaling pathways tied to oncogenesis and suggests a potential role as a therapeutic target (PMID: 24086155).",
            "molecularProfile": {
                "id": 2598,
                "profileName": "AGO1 amp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1138,
                    "pubMedId": 24086155,
                    "title": "Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24086155"
                },
                {
                    "id": 1374,
                    "pubMedId": 18685719,
                    "title": "Oncomirs: the potential role of non-coding microRNAs in understanding cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18685719"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1565,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In preclinical studies, researchers are developing inhibitors targeting NSD1 methyltransferase activity against cancers potentially driven by NSD1 amplification (PMID: 21664949, PMID: 21922056).",
            "molecularProfile": {
                "id": 2690,
                "profileName": "NSD1 amp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1537,
                    "pubMedId": 21922056,
                    "title": "An open and shut case for the role of NSD proteins as oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21922056"
                },
                {
                    "id": 1538,
                    "pubMedId": 21664949,
                    "title": "Cancers and the NSD family of histone lysine methyltransferases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21664949"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1567,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the broad spectrum kinase inhibitor midostaurin inhibited growth of cells dependent on the fusion protein ETV6-NTRK3, reducing ETV6-NTRK3 kinase activity and downstream signaling and inducing apoptosis (PMID: 23131561).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1543,
                    "pubMedId": 23131561,
                    "title": "ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23131561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1568,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, JUN over expression led to PAK3 over expression in transformed cells. Knock down of PAK3 did not prevent cell proliferation, but did prevent the morphological and migratory phenotype associated with transformation (PMID: 23818969).",
            "molecularProfile": {
                "id": 2697,
                "profileName": "JUN over exp PAK3 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1545,
                    "pubMedId": 23818969,
                    "title": "p21-activated kinase 3 (PAK3) is an AP-1 regulated gene contributing to actin organisation and migration of transformed fibroblasts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23818969"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1579,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "KDM2B over expression has been noted in both prostate cancer and leukemia. In a preclinical study, ectopic expression of Kdm2b resulted in the transformation of cultured cells while knockdown of expression using siRNA reduced cell survival, suggesting Kdm2b as a potential therapeutic target in cancer (PMID: 21596573).",
            "molecularProfile": {
                "id": 2702,
                "profileName": "KDM2B over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1575,
                    "pubMedId": 21596573,
                    "title": "Inhibitors of histone demethylases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21596573"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1597,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "The histone methyltransferase SETD7 influences expression of multiple genes related to cancer including p53 and the estrogen receptor (ER) (PMID: 21826189, PMID: 18471979). In a preclinical study, PFI-2 was demonstrated to be a selective inhibitor of Setd7 thus allowing further examination of its potential as a therapeutic target (PMID: 25136132).",
            "molecularProfile": {
                "id": 2734,
                "profileName": "SETD7 wild-type"
            },
            "therapy": {
                "id": 1931,
                "therapyName": "PFI-2",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1601,
                    "pubMedId": 25136132,
                    "title": "(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25136132"
                },
                {
                    "id": 1602,
                    "pubMedId": 21826189,
                    "title": "Regulation of p53 function by lysine methylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21826189"
                },
                {
                    "id": 1603,
                    "pubMedId": 18471979,
                    "title": "Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18471979"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1621,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "Dysregulation of the Hippo pathway has been reported in a variety of cancer types. In a preclinical study, Dobutamine was demonstrated to bind to the Hippo downstream effector Yap1 and prevent nuclear translocation and transcription of target genes. The ability to inhibit Yap1 function allows study into its potential role as a therapeutic target in cancer treatment (PMID: 21586534).",
            "molecularProfile": {
                "id": 2777,
                "profileName": "YAP1 wild-type"
            },
            "therapy": {
                "id": 1967,
                "therapyName": "Dobutamine",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1742,
                    "pubMedId": 21586534,
                    "title": "A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21586534"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2406,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7464,
                "profileName": "JAK2 R683G JAK2 E864K"
            },
            "therapy": {
                "id": 2785,
                "therapyName": "NVP-BSK805",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2407,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7464,
                "profileName": "JAK2 R683G JAK2 E864K"
            },
            "therapy": {
                "id": 2834,
                "therapyName": "NVP-BVB808",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2410,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7468,
                "profileName": "JAK2 R683G JAK2 G935R"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2413,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7468,
                "profileName": "JAK2 R683G JAK2 G935R"
            },
            "therapy": {
                "id": 2785,
                "therapyName": "NVP-BSK805",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2414,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7468,
                "profileName": "JAK2 R683G JAK2 G935R"
            },
            "therapy": {
                "id": 2834,
                "therapyName": "NVP-BVB808",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4472,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, advanced solid tumor cells overexpressing Rspo3 in culture and in patient-derived xenograft models demonstrated inhibition of beta-catenin activity and suppression of tumor growth when treated with RSPO3 specific antibodies, suggesting RSPO3 may be a promising therapeutic target (PMID: 26719531).",
            "molecularProfile": {
                "id": 18200,
                "profileName": "RSPO3 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4577,
                    "pubMedId": 26719531,
                    "title": "Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates \u03b2-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4694,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) S611R were resistant to inhibition by Cpd-5 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18827,
                "profileName": "TTK S611R"
            },
            "therapy": {
                "id": 3465,
                "therapyName": "Cpd-5",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4695,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) I598F were resistant to inhibition by Cpd-5 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18828,
                "profileName": "TTK I598F"
            },
            "therapy": {
                "id": 3465,
                "therapyName": "Cpd-5",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4699,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) S611R were resistant to inhibition by NMS-P715 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18827,
                "profileName": "TTK S611R"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4700,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) I598F were resistant to inhibition by NMS-P715 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18828,
                "profileName": "TTK I598F"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4703,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) S611R were resistant to inhibition by AZ3146 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18827,
                "profileName": "TTK S611R"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4704,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) I598F were resistant to inhibition by AZ3146 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18828,
                "profileName": "TTK I598F"
            },
            "therapy": {
                "id": 3117,
                "therapyName": "AZ3146",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4707,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) S611R were resistant to inhibition by MPS1-IN-3 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18827,
                "profileName": "TTK S611R"
            },
            "therapy": {
                "id": 3455,
                "therapyName": "MPS1-IN-3",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4709,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) S611R were resistant to inhibition by reversine (PMID: 26364596).",
            "molecularProfile": {
                "id": 18827,
                "profileName": "TTK S611R"
            },
            "therapy": {
                "id": 2327,
                "therapyName": "Reversine",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4714,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines expressing Ttk (Mps1) S611R were resistant to inhibition by MPI-0479605 (PMID: 26364596).",
            "molecularProfile": {
                "id": 18827,
                "profileName": "TTK S611R"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4449,
                    "pubMedId": 26364596,
                    "title": "Molecular basis underlying resistance to Mps1/TTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26364596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12171,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tandutinib (CT53518) inhibited phosphorylation of FLT3 and activation of ERK and STAT5, and reduced growth of transformed cells expressing FLT3 I836del in culture (PMID: 15256420).",
            "molecularProfile": {
                "id": 6640,
                "profileName": "FLT3 I836del"
            },
            "therapy": {
                "id": 933,
                "therapyName": "Tandutinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2706,
                    "pubMedId": 15256420,
                    "title": "Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256420"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12172,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited phosphorylation of FLT3, ERK, and STAT5, and growth of transformed cells expressing FLT3 I836del in culture (PMID: 17827387).",
            "molecularProfile": {
                "id": 6640,
                "profileName": "FLT3 I836del"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10126,
                    "pubMedId": 17827387,
                    "title": "Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17827387"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12271,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ARGX-110 demonstrated tolerability and some preliminary anti-tumor activity in patients with advanced solid tumors or hematological malignancies, with treatment resulting in stable disease as best response in 53.8% (14/26) patients (PMID: 28765328).",
            "molecularProfile": {
                "id": 28616,
                "profileName": "CD70 positive"
            },
            "therapy": {
                "id": 6400,
                "therapyName": "ARGX-110",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10230,
                    "pubMedId": 28765328,
                    "title": "Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765328"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02484053",
            "title": "Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03543358",
            "title": "A Long-Term Study of Rovalpituzumab Tesirine",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3544,
                    "therapyName": "Rovalpituzumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03768063",
            "title": "A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)",
            "phase": "FDA approved",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03844048",
            "title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial",
            "phase": "Phase III",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 1562,
                    "therapyName": "Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03899155",
            "title": "Pan Tumor Nivolumab Rollover Study",
            "phase": "FDA approved",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03912831",
            "title": "Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 9662,
                    "therapyName": "KITE-439",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03926143",
            "title": "A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies",
            "phase": "Phase II",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 4593,
                    "therapyName": "Anetumab ravtansine",
                    "synonyms": null
                }
            ]
        }
    ]
}